Some challenges to note with this approach include the lack of biomarkers that allow defining the microenvironment where these agents are most usefuland the potential risk of synchronous occult tumor growth by inhibiting the TGF-β suppressive action in early-stage cancers [54]. The gene discussed is TGFB1; the disease is cancer.